Rossari Biotech Share News - Latest Updates, Live News & More

Latest news about Rossari Biotech

Rossari Biotech Eyes Double-Digit Margin Expansion Through Performance Chemicals and Textile Specialties 3 days ago

Rossari Biotech achieved 17.60% YoY revenue growth in Q2 FY26, reaching 586.10 crore. EBITDA increased by 9.10% to 71.90 crore, while PAT grew 4.50% to 36.90 crore. Key segments showed robust growth: HPPC (16% YoY), TSC (21% YoY), and AHN (29% YoY). Exports surged 36% YoY, now contributing 28% to overall sales. The company expanded capacity at its Dahej facility to 152,500 MTPA and launched a 15,000 MTPA ethoxylation capacity at Unitop. The board approved an investment of up to $8 million in its Saudi Arabian subsidiary, RILC. Management expects continued growth driven by a diversified product portfolio, agile manufacturing, and international expansion.

Rossari Biotech Reports Robust Q2 FY26 Results, Approves Stock Options and Saudi Subsidiary Investment 4 days ago

Rossari Biotech Expands Dahej Facility, Boosts Production Capacity Sep 29, 2025

Rossari Biotech Boosts Manufacturing Capacity at Dahej Facility Sep 26, 2025

Rossari Biotech's Subsidiary Acquires Leasehold Land Rights in Gujarat for Rs 9 Crores Aug 18, 2025

More news about Rossari Biotech

25Jul 25

Rossari Biotech Reports 11% Revenue Growth to Rs 543.7 Crore in Q1, EBITDA Margins Decline

Rossari Biotech Limited reported an 11% year-on-year revenue growth to Rs 543.70 crore in Q1, driven by Home, Personal Care and Performance Chemicals (HPPC) and Animal Health and Nutrition (AHN) segments. EBITDA increased by 4.6% to Rs 67.90 crore, with a margin of 12.5%. The company faced production disruptions due to capacity expansion activities and challenges in export business. Management expects mid-double-digit growth of 14-15% for the full fiscal year and is setting up an overseas formulation facility in Southeast Asia.

20Jul 25

Rossari Biotech Reports Mixed Q1 Results with Higher EBITDA but Lower Margins

Rossari Biotech Limited announced Q1 financial results with consolidated revenue up 11% to ₹5,437.16 crore. EBITDA increased 4.8% to ₹680.00 crore, but EBITDA margin declined to 12.51%. Net profit decreased 3.7% to ₹335.96 crore. Home, Personal Care and Performance Chemicals segment grew 16%, while Animal Health and Nutrition segment increased 12% year-on-year. Management expressed confidence in ongoing efficiency initiatives and capacity expansion projects.

25Apr 25

Rossari Biotech Reports Q4 EBITDA Growth and Strong FY2023 Results, Announces Capacity Expansion

Rossari Biotech Limited reported robust Q4 FY2023 results with a 22.60% YoY revenue growth to ₹5.80 billion and a slight increase in net profit to ₹344.00 million. The company announced significant capacity expansion plans for itself and its subsidiaries, with a total investment of ₹192.00 crore. A final dividend of ₹0.50 per share was recommended. The expansion aims to accommodate new product lines, meet market demands, and enhance competitiveness in both domestic and export markets.

25Apr 25

Rossari Biotech's Subsidiaries Unveil Ambitious Capacity Expansion Plans

Rossari Biotech's subsidiaries, Unitop Chemicals and Tristar Intermediates, are set for significant capacity expansions. Unitop Chemicals plans to add 18,500 MTPA capacity with an investment of ₹77 crore, to be completed by Q4 FY 2025-26. Tristar Intermediates will increase capacity by 3,600 MTPA with a ₹20 crore investment, also expected to be commissioned by Q4 FY 2025-26. Both expansions aim to meet market demands, improve efficiency, and strengthen competitive positions in the specialty chemicals sector.